AzTrials
AzTrials

Acute Ischemic StrokeNCT05323266

Ventilation Modalities and Acute Ischemic Stroke

A study testing Nasal Continuous Positive Airway Pressure (nCPAP) and High-Flow Nasal Cannula (HFNC) in people with Acute Ischemic Stroke and Sleep Apnea, Obstructive, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Acute ischemic stroke is the second leading cause of death and disability, and it is also one of the main reasons for the high cost of health care. The major risk factors for stroke are hypertension, atrial fibrillation, and smoking, which are the main intervention targets for primary stroke prevention. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Nasal Continuous Positive Airway Pressure (nCPAP) and High-Flow Nasal Cannula (HFNC)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
195 participants
Where
1 siteChina
Study dates
1 May 2022to 15 Feb 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years
  • Clinical diagnosis of acute ischemic stroke and sleep apnea (AHI≥5/hour)
  • Definite cerebral infarct lesions on CT and MRI
  • National Institutes of Health Stroke Score (NIHSS) baseline score of 2-20
  • State of consciousness (Glasgow Coma Score of ≥9)
  • Semi-quantitative cough strength score of ≥2.

Who cannot join

  • Pre-existing obstructive sleep apnea
  • Suspected sleep disorders other than sleep apnea (e.g., episodic sleeping sickness)
  • Respiratory distress requiring mechanical ventilation
  • Oxygen-dependent chronic obstructive pulmonary disease
  • Pregnancy
  • Intracranial hemorrhage
Show all 13Show fewer
  • Inability to use a nasal mask or mask (e.g., facial trauma)
  • Patients who died within 24 h of admission
  • History of other neurological disorders such as Parkinson's disease, neuro infection, neuromuscular disease patients
  • Hospice care or comfort measures only
  • Inability to provide informed consent
  • Inability to provide valid information
  • Suicidal ideation.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Wuhan Union Hospital

    Wuhan, Hubei, 430022

Other trials in China

About this study

Official title: Effect of Different Ventilation Modalities on the Early Prognosis of Patients With Sleep Apnea After Acute Ischemic Stroke

Acute ischemic stroke is the second leading cause of death and disability, and it is also one of the main reasons for the high cost of health care. The major risk factors for stroke are hypertension, atrial fibrillation, and smoking, which are the main intervention targets for primary stroke prevention. Although these recognized risk factors have been adequately treated, there are also significant differences in stroke incidence and outcome in the population. Sleep apnea is a common complication of acute ischemic stroke, characterized by upper airway obstruction and obstructive sleep apnea.

Nowadays, more studies are currently investigating CPAP to promote long-term neurological recovery, improve the ability to perform activities of daily living, and reduce the recurrence of cardiovascular disease in stroke patients. However, 25%-50% of patients with sleep apnea will refuse or be intolerant of ventilation with CPAP. High-flow nasal cannula (HFNC) therapy is a revolutionary non-invasive respiratory support option that is widely used in NICU worldwide. This trial aims to investigate the value of different ventilation methods in reducing the rate of pulmonary infections and tracheal intubation in stroke patients.

This trial is a prospective randomized cohort study, collecting patients with acute ischemic stroke in the intensive care unit of the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from 2022.05.01 to 2023.01.31. Participants who met the inclusion criteria were subjected to polysomnography on the first day of admission, and those diagnosed with sleep apnea according to the diagnostic criteria for sleep apnea were randomly grouped. Participants were given different forms of oxygen therapy, such as usual care therapy (nasal cannula and facemask), nasal continuous positive airway pressure (nCPAP), and HFNC oxygen therapy. After one week of observation, the investigators evaluated whether there were differences in the rate of tracheal intubation and pulmonary infection between the groups, as well as the length of hospitalization, hospital costs, and neurological recovery. All enrolled patients were followed up 1 month after discharge.

Read the detailed description

Study population:

Participants with acute ischemic stroke in the intensive care unit of the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology were selected, with stroke onset within one week.

Diagnostic criteria:

Presence of clear clinical manifestations of acute ischemic stroke and clear cerebral infarct lesions on CT and MRI.

Content and Methods:

Participants who met the study criteria were selected based on inclusion and exclusion criteria. Participants who were included in this study were informed in detail of their condition and the purpose and significance of the current clinical study, and polysomnography monitoring was performed with the consent of the participants themselves or the participant's families. The diagnosis of sleep apnea was confirmed by a sleep apnea-hypopnea index (AHI) ≥5 events/h with nocturnal snoring or sleep apnea symptoms. Participants diagnosed with sleep apnea were grouped according to the principle of stratification and then randomization, (e.g., Glasgow Coma Scale for stratification 9-12, 13-14, and then randomization within each stratum). All participants with an AHI ≥5 events/h were randomized by computer-generated random numbers and the sheets (with numbers printed) were sealed in opaque envelopes. One envelope was opened by a clinical assistant each time a participant was to be randomized and information about the category mentioned in the sheet was then communicated to the sleep technologists in person or by telephone.

The study was divided into three groups, the usual care group (nasal cannula and facemask), the nasal continuous positive airway pressure (nCPAP) group, and the high-flow nasal cannula (HFNC) group. All participants included in the study recorded basic information, underlying disease, vital signs, stroke site and extent, and recorded AHI, obstructive apnea-hypopnea index (OAHI), oxygen desaturation index (ODI), SpO2, and presence of complications, and also assessed the NIHSS, Barthel Index, modified Rankin scale (mRS), and Aspects score. All participants included in this study were treated with different ventilation modalities for one week, and the length of use, compliance, and side effects of participants with different ventilation modalities were recorded during the treatment period. After one week, the investigators assessed whether there were differences in the rates of tracheal intubation and pulmonary infection among the groups, as well as the length of hospitalization, hospital expenses, mortality, and neurological recovery after one month of discharge.

In this study, acute ischemic stroke patients with undiagnosed sleep apnea were treated with routine nasal catheter oxygenation, while basic information, underlying disease, vital signs, stroke site and extent, and AHI, OAHI, ODI, SpO2, and presence of complications were recorded, and the NIHSS, Barthel Index, mRS, and Aspects score were also evaluated. All participants underwent multiple polysomnography monitoring, which was completed 1, 3, 5, and 7 days after admission, to record whether acute ischemic stroke patients would develop sleep apnea in the acute phase and the changes in stroke participants' condition when sleep apnea appeared, to lay the foundation for better prevention or early intervention of sleep apnea in stroke patients.

nCPAP therapy: Initial pressure support of 6-8 cmH2O through a nasal mask, pressure titration of CPAP during sleep, and adjustment of CPAP pressure until apnea and hypoventilation are eliminated.

HFNC therapy:

Initial flow rate is set at 20 L/min. titrated after sleep, with each flow rate increasing by 10 L/min up to 60 L/min in an attempt to eliminate apnea and hypoventilation in the supine position or during fast-acting eye sleep.

Polysomnography:

All participants included in this study will be monitored by polysomnography, which is performed during the time of the participant's sleep and is obtained by a trained technician, and the scoring and analysis are performed by the technician during polysomnography acquisition. Apnea-hypopnea index (AHI): the sum of the average number of apnea and hypoventilation per hour during sleep. Sleep apnea is diagnosed when the apnea index AHI is ≥5 events/h. Sleep apnea (SA): absence or significant reduction (≥90% decrease from baseline amplitude) of oral and nasal airflow during sleep for ≥10 s. Hypopnea: ≥30% decrease in oronasal airflow from baseline level with ≥4% decrease in pulse oximetry (SpO2) during sleep for ≥10s; or ≥50% decrease in oronasal airflow from baseline level with ≥3% decrease in SpO2 for ≥10s. Oxygen desaturation index (ODI): the number of decreases in oxygen saturation ≥ 3% per hour on average.

Sample size:

This study is a prospective randomized cohort study, in which the test level is α = 0.05 and the test efficiency is 1-β = 0.9. According to the number of hospitalized patients with acute ischemic stroke in this study unit and the current incidence of sleep apnea after stroke (60%-80%), and taking into account the possibility that the patient's condition deteriorated during hospitalization and did not meet the inclusion criteria, the final sample size is expected to be 150.

Study indicators:

Participants (all on the first day of admission) were recorded for: basic information including gender, age, underlying disease, history of smoking and drinking, BMI, neck circumference, waist circumference; vital signs including heart rate, respiratory rate, blood pressure, body temperature, SpO2; relevant laboratory test indicators including lactic acid, creatinine, total bilirubin, B-type natriuretic peptide, leukocytes, procalcitonin, C-reactive protein, IL-6; cranial magnetic resonance imaging, pulmonary computed tomography, cervical vascular ultrasound, polysomnography results AHI; relevant scores including semi-quantitative cough strength score, APACHE II, GCS score, NIHSS score, Barthel index, mRS score, Aspects score, etc.

Data collection and management:

The data for this study were obtained from the medical records of patients at the Wuhan Union Hospital, and the results of the patients' examinations were collected and analyzed. All the data are clear and accurate, have traceability, establish a clinical database, the database is protected by a password, and the database is established by the logical proofreading program. In this study, participants are not identified by name. Post-discharge follow-up is achieved through each participant's unique number and telephone number at the time of admission. The principal investigator (PI) of the study will have access to the final study data set.

Research data retention:

All original data and documents required in this project shall be saved at least three years after the end of the clinical trial and shall be approved before destruction.

Statistical Analysis:

SPSS 22.0 was applied for data analysis in this study, and the classification of data types was the first step in conducting statistical analysis. Testing the continuous variables in the study for normality was assessed by the Kolmogorov-Smirnov test. The Mann-Whitney U test was used to analyze continuous variables in this study. Categorical variables were expressed as frequencies and compared using the chi-square test or Fisher's exact test. Multivariate logistic regression analysis and ROC curve were used to evaluate the prognostic factors of different ventilation modes in patients with sleep apnea after acute stroke. At the same time, the Kaplan-Meier survival curve in SPSS 22.0 software was used to compare the prognosis of patients with acute ischemic stroke in different groups. All statistical analyses will be performed by SPSS 22.0 (IBM SPSS Statistics 22.0, SPSS Inc., Chicago, IL) and R language (version 4.1.3, www.R-project.org/). Statistical significance is expressed as P<0.05.

Quality control:

Since different physicians have different clinical experiences and may have different scores, each patient's assessment was evaluated and scored by the same physician to ensure the accuracy and sameness of the scoring criteria each time, and repeated training was given to the performers several times before conducting the assessment.

Safety evaluation:

This study aims to investigate the early prognosis study of patients with sleep apnea after acute ischemic stroke using different oxygen therapy modalities, which is beneficial to the prognosis of stroke patients and does not cause harm to the patients themselves. If the patient's condition deteriorates during the study, the treatment plan will be adjusted according to the patient's actual condition promptly, and tracheal intubation or tracheotomy will be performed if necessary.

The Informed Consent Process:

Informed consent is completed before the study subject's consent to participate in the study and continues throughout the study. Informed consent is agreed to by the ethics committee, and study subjects are expected to read the informed consent form. The investigator will explain the study process and answer questions from the subject, and inform the subject of the possible risks and their rights. Subjects may discuss this with their families or guardians before consenting to participate. The investigator must inform the subject that participation in the study is voluntary and that they may withdraw from the study at any time during the study. Copies of the informed consent form may be provided to study subjects for their records. The rights and welfare of the study subjects will be protected and it is emphasized that the quality of their medical care will not be compromised by refusal to participate in the study.

Privacy Protection:

All information collected in this study is managed with special confidentiality, and any study information cannot be disclosed to unauthorized third parties without prior approved consent.

Declarations of interest:

The authors have disclosed that they do not have any conflicts of interest.

Being tested
Nasal Continuous Positive Airway Pressure (nCPAP), High-Flow Nasal Cannula (HFNC)
Keywords
Acute Ischemic Stroke, Sleep Apnea, Apnea-Hypopnea Index
Medical subject headings
Ischemic Stroke, Sleep Apnea, Obstructive, Sleep Apnea Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nasal Continuous Positive Airway Pressure (nCPAP)Device

    The two main interventions in this study were Nasal continuous positive airway pressure (nCPAP) and high-flow nasal cannula (HFNC) in patients with acute stroke. Nasal continuous positive airway pressure (nCPAP) is a way of ventilation completed in a non-invasive ventilator. In this study, the nasal mask is mainly used to replace the traditional oral and nasal mask.

  • High-Flow Nasal Cannula (HFNC)Device

    The high-flow nasal cannula (HFNC), as another oxygen therapy, is also used as an intervention in this study to study the effect of early prognosis in patients with acute ischemic stroke.

Study groups in NCT05323266
Study groupRoleWhat they receive
Nasal Continuous Positive Airway Pressure (nCPAP)ExperimentalNasal Continuous Positive Airway Pressure is the main mode of oxygen supply observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
Receives: Device: Nasal Continuous Positive Airway Pressure (nCPAP)
High-Flow Nasal Cannula (HFNC)ExperimentalNasalContinuousPositiveAirwayPressure is another oxygen supply mode mainly observed in this study, and this group of patients only use this oxygen supply mode to receive oxygen therapy after stroke.
Receives: Device: High-Flow Nasal Cannula (HFNC)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Tracheal Intubation Rate

    To observe the change of tracheal intubation rate between different groups after 1 week of ventilation in patients with acute ischemic stroke using different ventilation methods after admission.

    Measured: one week

  2. Pulmonary Infection Status

    To observe the change in the rate of pulmonary infection between different groups after 1 week of ventilation in patients with acute ischemic stroke using different ventilation methods after admission

    Measured: one week

  3. 28-day mortality rate

    Patients with acute ischemic stroke were treated with different modes of ventilation after admission to observe whether there was any difference in 28-day mortality among different groups of patients.

    Measured: 28 days

Secondary outcomes (6)
  1. National Institute of Health stroke scale (NIHSS)

    NIHSS was used to evaluate the severity of stroke patients. Changes of NIHSS scores in patients with acute stroke after one week of different ventilation modes. NIHSS scores range from 0-42, with higher scores indicating more severe nerve damage.

    Measured: one week

  2. Barthel Index

    Barthel Index was used to evaluate the ability of stroke patients to live independently in the later stage, and whether the quality of life of patients with acute ischemic stroke was improved in 1 month.

    Measured: 1 month

  3. Sleep Apnea Symptoms

    Changes of sleep apnea symptoms in patients with acute ischemic stroke after one week of different ventilation treatment. After 1 week of treatment with different ventilation modalities, polysomnography monitoring was done again to assess whether sleep was improved in stroke patients by calculating the magnitude of the apnea-hypopnea index (AHI) value. the minimum value of AHI is 0 and there is no maximum value, the larger its value, the more severe the sleep apnea symptoms.

    Measured: one week

  4. Time of Hospitalization

    To assess whether the length of stay in hospital is prolonged in stroke patients in different ventilation groups.

    Measured: From date of randomization until the date of death from any cause or discharge, whichever came first, assessed up to 3 months.

  5. Cost of Hospitalization

    To assess whether the cost of hospitalization increases for stroke patients in different ventilation groups.

    Measured: From date of randomization until the date of death from any cause or discharge, whichever came first, assessed up to 3 months.

  6. Neurological Recovery (modified Rankin scale)

    To evaluate the recovery of neurological function in patients with acute stroke between different ventilation groups within 1 month. The modified Rankin scale ranges from 0-6, with higher scores suggesting poorer neurological recovery in stroke patients.

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2022
  2. Study start1 May 2022
  3. Primary completion8 Jan 2023
  4. Study completion15 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients with acute ischemic stroke were admitted to the Intensive Care Unit of the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients were diagnosed with sleep apnea after polysomnography monitoring. They were divided into 3 groups according to the randomization principle, the usual care group (nasal cannula or mask), the nasal continuous positive airway pressure (nCPAP) group, and the high-flow nasal cannula (HFNC) group. In this study, nCPAP and HFNC were used as 2 different interventions in comparison to the usual care group.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
195 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05323266
Sponsor's protocol ID
NICU0110WXR
Status last verified
Mar 2023
First submitted
25 Mar 2022
Last updated
22 Mar 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The members of the project team agreed to share all collected individual participant data with other researchers, including the study protocol and statistical analysis plan (SAP).

Publications

  • Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005 Nov 10;353(19):2034-41. doi: 10.1056/NEJMoa043104.

    PubMed 16282178
  • Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O'Connor GT, Resnick HE, Diener-West M, Sanders MH, Wolf PA, Geraghty EM, Ali T, Lebowitz M, Punjabi NM. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2010 Jul 15;182(2):269-77. doi: 10.1164/rccm.200911-1746OC. Epub 2010 Mar 25.

    PubMed 20339144
  • Gottlieb E, Landau E, Baxter H, Werden E, Howard ME, Brodtmann A. The bidirectional impact of sleep and circadian rhythm dysfunction in human ischaemic stroke: A systematic review. Sleep Med Rev. 2019 Jun;45:54-69. doi: 10.1016/j.smrv.2019.03.003. Epub 2019 Mar 20.

    PubMed 30954762
  • Tanayapong P, Kuna ST. Sleep disordered breathing as a cause and consequence of stroke: A review of pathophysiological and clinical relationships. Sleep Med Rev. 2021 Oct;59:101499. doi: 10.1016/j.smrv.2021.101499. Epub 2021 Apr 30.

    PubMed 34020180
  • Lin HJ, Yeh JH, Hsieh MT, Hsu CY. Continuous positive airway pressure with good adherence can reduce risk of stroke in patients with moderate to severe obstructive sleep apnea: An updated systematic review and meta-analysis. Sleep Med Rev. 2020 Dec;54:101354. doi: 10.1016/j.smrv.2020.101354. Epub 2020 Jul 15.

    PubMed 32755811
  • Parra O, Sanchez-Armengol A, Bonnin M, Arboix A, Campos-Rodriguez F, Perez-Ronchel J, Duran-Cantolla J, de la Torre G, Gonzalez Marcos JR, de la Pena M, Carmen Jimenez M, Masa F, Casado I, Luz Alonso M, Macarron JL. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Respir J. 2011 May;37(5):1128-36. doi: 10.1183/09031936.00034410. Epub 2010 Sep 16.

    PubMed 20847081
  • Rochwerg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y, Goligher EC, Jaber S, Ricard JD, Rittayamai N, Roca O, Antonelli M, Maggiore SM, Demoule A, Hodgson CL, Mercat A, Wilcox ME, Granton D, Wang D, Azoulay E, Ouanes-Besbes L, Cinnella G, Rauseo M, Carvalho C, Dessap-Mekontso A, Fraser J, Frat JP, Gomersall C, Grasselli G, Hernandez G, Jog S, Pesenti A, Riviello ED, Slutsky AS, Stapleton RD, Talmor D, Thille AW, Brochard L, Burns KEA. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. Intensive Care Med. 2020 Dec;46(12):2226-2237. doi: 10.1007/s00134-020-06312-y. Epub 2020 Nov 17.

    PubMed 33201321
  • Yan H, Qinghua L, Mengyuan P, Yaoyu C, Long Z, Mengjie L, Xiaosong D, Fang H. High flow nasal cannula therapy for obstructive sleep apnea in adults. Sleep Breath. 2022 Jun;26(2):783-791. doi: 10.1007/s11325-021-02453-6. Epub 2021 Aug 12.

    PubMed 34383275
  • Nakanishi N, Suzuki Y, Ishihara M, Ueno Y, Tane N, Tsunano Y, Itagaki T, Oto J. Effect of High-Flow Nasal Cannula on Sleep-disordered Breathing and Sleep Quality in Patients With Acute Stroke. Cureus. 2020 Jul 20;12(7):e9303. doi: 10.7759/cureus.9303.

    PubMed 32832300
  • Ho CH, Chen CL, Yu CC, Yang YH, Chen CY. High-flow nasal cannula ventilation therapy for obstructive sleep apnea in ischemic stroke patients requiring nasogastric tube feeding: a preliminary study. Sci Rep. 2020 May 22;10(1):8524. doi: 10.1038/s41598-020-65335-z.

    PubMed 32444630
  • Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21.

    PubMed 34148375
  • Li Z, Pang M, Yu Y, Peng T, Hu Z, Niu R, Wang X, Zhang J. Effect of different ventilation modalities on the early prognosis of patients with sleep apnea after acute ischemic stroke---protocol for a prospective, open-label and randomised controlled trial. BMC Neurol. 2023 Jun 6;23(1):215. doi: 10.1186/s12883-023-03117-6.

    PubMed 37280508

Questions about this trial

What is this clinical trial studying?

A study testing Nasal Continuous Positive Airway Pressure (nCPAP) and High-Flow Nasal Cannula (HFNC) in people with Acute Ischemic Stroke and Sleep Apnea, Obstructive, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Tracheal Intubation Rate (time frame: one week). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05323266, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2023; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in